MXPA02006511A - Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido. - Google Patents

Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.

Info

Publication number
MXPA02006511A
MXPA02006511A MXPA02006511A MXPA02006511A MXPA02006511A MX PA02006511 A MXPA02006511 A MX PA02006511A MX PA02006511 A MXPA02006511 A MX PA02006511A MX PA02006511 A MXPA02006511 A MX PA02006511A MX PA02006511 A MXPA02006511 A MX PA02006511A
Authority
MX
Mexico
Prior art keywords
complex
polysaccharide
ocif
group
substance selected
Prior art date
Application number
MXPA02006511A
Other languages
English (en)
Inventor
Junichi Kondo
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of MXPA02006511A publication Critical patent/MXPA02006511A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un complejo novedoso que comprende por lo menos una sustancia seleccionada del grupo que consiste de factor inhibidor de osteoclastogenesis, OCIF, analogos del mismo y variantes del mismo, el cual se une a por lo menos una sustancia seleccionada del grupo que consiste de polisacaridos y derivados de los mismos, muestra retencion prolongada en la corriente sanguinea despues de su administracion, haciendolo util en el tratamiento y profilaxis de enfermedades metabolicas oseas.
MXPA02006511A 2001-06-29 2002-06-28 Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido. MXPA02006511A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29

Publications (1)

Publication Number Publication Date
MXPA02006511A true MXPA02006511A (es) 2004-08-11

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02006511A MXPA02006511A (es) 2001-06-29 2002-06-28 Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.

Country Status (22)

Country Link
US (3) US20030045456A1 (es)
EP (1) EP1270015A3 (es)
KR (1) KR20030003124A (es)
CN (1) CN1442201A (es)
AR (1) AR034716A1 (es)
AU (1) AU783126B2 (es)
BR (1) BR0202439A (es)
CA (1) CA2392383A1 (es)
CO (1) CO5390084A1 (es)
CZ (1) CZ20022231A3 (es)
HK (1) HK1048762A1 (es)
HU (1) HUP0202119A2 (es)
IL (1) IL150448A0 (es)
MX (1) MXPA02006511A (es)
NO (1) NO20023144L (es)
PA (1) PA8549401A1 (es)
PE (1) PE20030254A1 (es)
PL (1) PL354799A1 (es)
RU (1) RU2232594C2 (es)
SG (1) SG98059A1 (es)
SK (1) SK9492002A3 (es)
ZA (1) ZA200205164B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
JP3860415B2 (ja) 1998-10-28 2006-12-20 三共株式会社 骨代謝異常症治療剤
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
AU2003208621A1 (en) * 2002-03-01 2003-09-16 Sankyo Company, Limited A pharmaceutical composition
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
CN1658895A (zh) 2002-04-10 2005-08-24 应用研究系统Ars股份公司 护骨素在治疗和／或预防纤维变性疾病中的应用
WO2003103710A1 (ja) * 2002-06-07 2003-12-18 三共株式会社 骨破壊の治療または予防剤組成物の併用効果
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207A (en) * 1845-09-27 lewis
US139325A (en) * 1873-05-27 Improvement in carriage-springs
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US31725A (en) * 1861-03-19 Improvement in cultivators
US181418A (en) * 1876-08-22 Improvement in gas apparatus
TW318142B (es) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0974671B1 (en) * 1997-09-24 2006-05-31 Sankyo Company, Limited Method for diagnosing bone dysbolism
DE69904818T2 (de) * 1998-06-15 2003-10-09 Takeda Chemical Industries Ltd Thienodipyridinderivate, ihre herstellung und verwendung
JP3860415B2 (ja) * 1998-10-28 2006-12-20 三共株式会社 骨代謝異常症治療剤
HUP0104688A3 (en) * 1999-09-03 2004-07-28 Amgen Inc Thousand Oaks Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
EP1379127B1 (en) * 2000-09-28 2013-04-17 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
AU2003208621A1 (en) * 2002-03-01 2003-09-16 Sankyo Company, Limited A pharmaceutical composition

Also Published As

Publication number Publication date
AU783126B2 (en) 2005-09-29
PL354799A1 (en) 2002-12-30
NO20023144L (no) 2002-12-30
EP1270015A3 (en) 2004-02-25
AU5071902A (en) 2003-01-02
RU2002117385A (ru) 2004-01-27
BR0202439A (pt) 2003-06-10
IL150448A0 (en) 2002-12-01
KR20030003124A (ko) 2003-01-09
CO5390084A1 (es) 2004-04-30
US20030045456A1 (en) 2003-03-06
CN1442201A (zh) 2003-09-17
HK1048762A1 (zh) 2003-04-17
AR034716A1 (es) 2004-03-17
US20060084595A1 (en) 2006-04-20
RU2232594C2 (ru) 2004-07-20
ZA200205164B (en) 2003-03-24
CA2392383A1 (en) 2002-12-29
HU0202119D0 (es) 2002-08-28
SK9492002A3 (en) 2003-02-04
PE20030254A1 (es) 2003-03-19
NO20023144D0 (no) 2002-06-28
HUP0202119A2 (hu) 2003-04-28
PA8549401A1 (es) 2003-07-28
US20030139325A1 (en) 2003-07-24
EP1270015A2 (en) 2003-01-02
CZ20022231A3 (cs) 2003-02-12
SG98059A1 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EP1830191A3 (en) Pharmaceutical preparations containing thiazolidinediones for the treatment of endocrine autoimmune diseases
HK1068606A1 (en) Novel aminobenzoephenones
ZA200303037B (en) Herbal pharmaceutical composition for treatment of HIV/Aids patients.
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
AU2002366433A1 (en) Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
DK1643999T3 (da) Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
IL150541A0 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
WO2004071398A3 (en) Pharmaceutical patch
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2004030684A3 (en) Kavalactone product
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
DE60037402D1 (de) Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng